Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005606 · ClinicalTrials.gov registry record · Phase 2
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005606 is a Phase 2 study that has completed, run by Northwestern University.
The verdict
NCT00005606, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation. PURPOSE: Phase II trial to study the effectiveness of peripheral blood lymphocyte therapy in treating and preventing lymphoproliferative disorders in patients who have Epstein-Barr virus infection following transplantation.
Interventions
- BIOLOGICAL allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
- BIOLOGICAL autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005606
The ClinicalTrials.gov registry entry for NCT00005606 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes is the first listed.
NCT00005606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005606 about?
NCT00005606 is a clinical study titled "Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation". RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation. PURPOSE: Phase II trial to study the effectiveness of peripheral blood lymphocyte therapy in treating and preventing lymphoproliferative disorde...
What is the current status of trial NCT00005606?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-02. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00005606?
The interventions under investigation include: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes (BIOLOGICAL), autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005606?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.